Therapeutic Activity of Medroxyprogesterone Acetate in Metastatic Breast Cancer: A Correlation Between Estrogen Receptors and Various Dosages

  • M. De Lena
  • S. Villa
  • G. Di Fronzo
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 91)


It has been known for a relatively long time that progestogens, and especially medroxyprogesterone acetate (MPA), induce objective regression of the neoplasia in women with metastatic breast cancer. Some authors have recently reported [1, 7–9] that the response to MPA may be increased by employing high daily dosages. On this basis, we tested different dosages of MPA in patients who had become resistant to combined chemotherapy. Furthermore, we correlated the response of the patient with estrogen receptor status of the tumor.


Metastatic Breast Cancer Objective Response Estrogen Receptor Status Medroxyprogesterone Acetate High Daily Dosage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Amadori D, Ravaioli A, Barbanti F (1977) The use of medroxyprogesterone acetate in high doses in palliative treatment of advanced mammary carcinoma (clinical experience with 44 cases). Minerva Med 68: 3967–3980PubMedGoogle Scholar
  2. 2.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–259PubMedCrossRefGoogle Scholar
  3. 3.
    De Lena M, Brambilla C, Volagussa P, Bonadonna G (1979) High dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2: 175–180PubMedCrossRefGoogle Scholar
  4. 4.
    De Lena M, Brambilla C, Jirillo A (1980) Tamoxifen efficacy in advanced breast cancer previously treated with endocrine and cytotoxic therapy. Tumori 66: 339–348PubMedGoogle Scholar
  5. 5.
    Di Fronzo G, Bertuzzi A, Ronchi E (1968) An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer. Tumori 64: 259–266Google Scholar
  6. 6.
    Ganzina F (1979) High dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review. Tumori 65: 563–585PubMedGoogle Scholar
  7. 7.
    Pannuti F, Martoni A, Lenaz CR, Piana E, Manni P (1978) A possible new approach to the treatment of metastatic breast cancer: Massive dose of medroxyprogesterone acetate. Cancer Treat Rep 62: 499–504PubMedGoogle Scholar
  8. 8.
    Pannuti F, Martoni A, Di Marco AR, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnuolo F, Polenzana D, Rocchetta G (1979) Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate ( MPA) in the treatment of metastatic breast cancer. J Cancer 15: 593–601Google Scholar
  9. 9.
    Robustelli Della Cuna G, Calciati A, Bernando Strada MR, Bumma C, Campio L (1978) High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a due response evolution. Tumori 64: 143–150Google Scholar
  10. 10.
    Scatchard G (1949) The attraction of protein for small molecules and ions. Ann NY Acad Sci 51: 660–672CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1984

Authors and Affiliations

  • M. De Lena
    • 1
  • S. Villa
    • 1
  • G. Di Fronzo
    • 1
  1. 1.Ospedale oncologicoBariItaly

Personalised recommendations